IONIS PHARMACEUTICALS INC — Director's Dealing 2012

Oct 4, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Regulus Therapeutics Inc. (RGLS)
CIK: 0001505512
Period of Report: 2012-10-04

Reporting Person: ISIS PHARMACEUTICALS INC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (6299500)		Direct

Footnotes

F1: The Series A Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will convert upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of Common Stock for every 2 shares of Series A Preferred Stock, for no additional consideration.

F2: Stanley T. Crooke, M.D., Ph.D. and B. Lynne Parshall are each officers and directors of the Reporting Person and therefore may be deemed to have control and indirect beneficial ownership of shares held by the Reporting Person. Dr. Crooke and Ms. Parshall disclaim beneficial ownership over the shares held by the Reporting Person, except to the extent of their respective proportionate pecuniary interests therein.